ID   TNIP1_HUMAN             Reviewed;         636 AA.
AC   Q15025; A4F1W8; A4F1W9; A4F1X2; A4F1X4; A4F1X5; A4F1X6; A4F1X7; A4F1X9;
AC   B7Z699; E7EPY1; E7ET96; O76008; Q05KP3; Q05KP4; Q6N077; Q96EL9; Q99833;
AC   Q9H1J3;
DT   23-JAN-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1999, sequence version 2.
DT   07-APR-2021, entry version 191.
DE   RecName: Full=TNFAIP3-interacting protein 1;
DE   AltName: Full=A20-binding inhibitor of NF-kappa-B activation 1;
DE            Short=ABIN-1;
DE   AltName: Full=HIV-1 Nef-interacting protein;
DE   AltName: Full=Nef-associated factor 1;
DE            Short=Naf1;
DE   AltName: Full=Nip40-1;
DE   AltName: Full=Virion-associated nuclear shuttling protein;
DE            Short=VAN;
DE            Short=hVAN;
GN   Name=TNIP1; Synonyms=KIAA0113, NAF1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Peripheral blood;
RX   PubMed=9923610; DOI=10.1016/s0014-5793(98)01631-7;
RA   Fukushi M., Dixon J., Kimura T., Tsurutani N., Dixon M.J., Yamamoto N.;
RT   "Identification and cloning of a novel cellular protein Naf1, Nef-
RT   associated factor 1, that increases cell surface CD4 expression.";
RL   FEBS Lett. 442:83-88(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Leukocyte;
RX   PubMed=11090181; DOI=10.1128/jvi.74.24.11811-11824.2000;
RA   Gupta K., Ott D., Hope T.J., Siliciano R.F., Boeke J.D.;
RT   "A human nuclear shuttling protein that interacts with human
RT   immunodeficiency virus type 1 matrix is packaged into virions.";
RL   J. Virol. 74:11811-11824(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3; 4; 5; 6; 7 AND 8),
RP   ALTERNATIVE SPLICING, TISSUE SPECIFICITY, AND FUNCTION.
RX   PubMed=17016622;
RA   Shiote Y., Ouchida M., Jitsumori Y., Ogama Y., Matsuo Y., Ishimaru F.,
RA   Tanimoto M., Shimizu K.;
RT   "Multiple splicing variants of Naf1/ABIN-1 transcripts and their
RT   alterations in hematopoietic tumors.";
RL   Int. J. Mol. Med. 18:917-923(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Bone marrow;
RX   PubMed=7788527; DOI=10.1093/dnares/2.1.37;
RA   Nagase T., Miyajima N., Tanaka A., Sazuka T., Seki N., Sato S., Tabata S.,
RA   Ishikawa K., Kawarabayasi Y., Kotani H., Nomura N.;
RT   "Prediction of the coding sequences of unidentified human genes. III. The
RT   coding sequences of 40 new genes (KIAA0081-KIAA0120) deduced by analysis of
RT   cDNA clones from human cell line KG-1.";
RL   DNA Res. 2:37-43(1995).
RN   [5]
RP   SEQUENCE REVISION.
RX   PubMed=12168954; DOI=10.1093/dnares/9.3.99;
RA   Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.;
RT   "Construction of expression-ready cDNA clones for KIAA genes: manual
RT   curation of 330 KIAA cDNA clones.";
RL   DNA Res. 9:99-106(2002).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Colon endothelium;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A.,
RA   Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R.,
RA   Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L.,
RA   Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N.,
RA   Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J.,
RA   Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A.,
RA   Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 136-636 (ISOFORM 2).
RC   TISSUE=Craniofacial;
RX   PubMed=8681136; DOI=10.1101/gr.6.1.26;
RA   Loftus S.K., Dixon J., Koprivnikar K., Dixon M.J., Wasmuth J.J.;
RT   "Transcriptional map of the Treacher Collins candidate gene region.";
RL   Genome Res. 6:26-34(1996).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 94-412.
RA   Fukushi M., Kimura T., Yamamoto N.;
RL   Submitted (JAN-1997) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   FUNCTION, AND INTERACTION WITH MAPK1.
RX   PubMed=12220502; DOI=10.1016/s0006-291x(02)02086-7;
RA   Zhang S., Fukushi M., Hashimoto S., Gao C., Huang L., Fukuyo Y.,
RA   Nakajima T., Amagasa T., Enomoto S., Koike K., Miura O., Yamamoto N.,
RA   Tsuchida N.;
RT   "A new ERK2 binding protein, Naf1, attenuates the EGF/ERK2 nuclear
RT   signaling.";
RL   Biochem. Biophys. Res. Commun. 297:17-23(2002).
RN   [14]
RP   FUNCTION, AND INTERACTION WITH IKBKG AND TNFAIP3.
RX   PubMed=16684768; DOI=10.1074/jbc.m601502200;
RA   Mauro C., Pacifico F., Lavorgna A., Mellone S., Iannetti A., Acquaviva R.,
RA   Formisano S., Vito P., Leonardi A.;
RT   "ABIN-1 binds to NEMO/IKKgamma and co-operates with A20 in inhibiting NF-
RT   kappaB.";
RL   J. Biol. Chem. 281:18482-18488(2006).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-403, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein phosphorylation
RT   analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [16]
RP   FUNCTION, INTERACTION WITH SELPLG AND PIK3CD, PHOSPHORYLATION AT TYR-552,
RP   AND MUTAGENESIS OF TYR-552.
RX   PubMed=17632516; DOI=10.1038/ni1491;
RA   Wang H.B., Wang J.T., Zhang L., Geng Z.H., Xu W.L., Xu T., Huo Y., Zhu X.,
RA   Plow E.F., Chen M., Geng J.G.;
RT   "P-selectin primes leukocyte integrin activation during inflammation.";
RL   Nat. Immunol. 8:882-892(2007).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-403, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-438, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [20]
RP   FUNCTION, INTERACTION WITH SHIGELLA FLEXNERI IPAH9.8, AND MUTAGENESIS OF
RP   476-GLU-ARG-477.
RX   PubMed=20010814; DOI=10.1038/ncb2006;
RA   Ashida H., Kim M., Schmidt-Supprian M., Ma A., Ogawa M., Sasakawa C.;
RT   "A bacterial E3 ubiquitin ligase IpaH9.8 targets NEMO/IKKgamma to dampen
RT   the host NF-kappaB-mediated inflammatory response.";
RL   Nat. Cell Biol. 12:66-73(2010).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-403 AND SER-442, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [22]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [23]
RP   UBIQUITIN-BINDING, AND MUTAGENESIS OF ASP-472.
RX   PubMed=21606507; DOI=10.1084/jem.20102177;
RA   Nanda S.K., Venigalla R.K., Ordureau A., Patterson-Kane J.C., Powell D.W.,
RA   Toth R., Arthur J.S., Cohen P.;
RT   "Polyubiquitin binding to ABIN1 is required to prevent autoimmunity.";
RL   J. Exp. Med. 208:1215-1228(2011).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-403 AND SER-627, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-77 AND SER-284, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [26]
RP   METHYLATION [LARGE SCALE ANALYSIS] AT ARG-599, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.o113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M.,
RA   Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V.,
RA   Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [27]
RP   VARIANTS TRP-263; MET-286; THR-374 AND LYS-476.
RX   PubMed=21266526; DOI=10.1158/1078-0432.ccr-10-1859;
RA   Dong G., Chanudet E., Zeng N., Appert A., Chen Y.W., Au W.Y., Hamoudi R.A.,
RA   Watkins A.J., Ye H., Liu H., Gao Z., Chuang S.S., Srivastava G., Du M.Q.;
RT   "A20, ABIN-1/2, and CARD11 mutations and their prognostic value in
RT   gastrointestinal diffuse large B-cell lymphoma.";
RL   Clin. Cancer Res. 17:1440-1451(2011).
CC   -!- FUNCTION: Inhibits NF-kappa-B activation and TNF-induced NF-kappa-B-
CC       dependent gene expression by regulating A20/TNFAIP3-mediated
CC       deubiquitination of IKBKG; proposed to link A20/TNFAIP3 to
CC       ubiquitinated IKBKG. Involved in regulation of EGF-induced ERK1/ERK2
CC       signaling pathway; blocks MAPK3/MAPK1 nuclear translocation and MAPK1-
CC       dependent transcription. Increases cell surface CD4(T4) antigen
CC       expression. Involved in the anti-inflammatory response of macrophages
CC       and positively regulates TLR-induced activation of CEBPB. Involved in
CC       the prevention of autoimmunity; this function implicates binding to
CC       polyubiquitin. Involved in leukocyte integrin activation during
CC       inflammation; this function is mediated by association with SELPLG and
CC       dependent on phosphorylation by SRC-family kinases. Interacts with HIV-
CC       1 matrix protein and is packaged into virions and overexpression can
CC       inhibit viral replication. May regulate matrix nuclear localization,
CC       both nuclear import of PIC (Preintegration complex) and export of GAG
CC       polyprotein and viral genomic RNA during virion production. In case of
CC       infection, promotes association of IKBKG with Shigella flexneri E3
CC       ubiquitin-protein ligase ipah9.8 p which in turn promotes
CC       polyubiquitination of IKBKG leading to its proteasome-dependent
CC       degradation and thus is perturbing NF-kappa-B activation during
CC       bacterial infection. {ECO:0000269|PubMed:12220502,
CC       ECO:0000269|PubMed:16684768, ECO:0000269|PubMed:17016622,
CC       ECO:0000269|PubMed:17632516, ECO:0000269|PubMed:20010814}.
CC   -!- SUBUNIT: Interacts with TNFAIP3 and IKBKG (polyubiquitinated);
CC       facilitates TNFAIP3-mediated de-ubiquitination of NEMO/IKBKG. Interacts
CC       with polyubiquitin. Interacts with MAPK1, SELPLG and PIK3CD. Interacts
CC       with IRAK1 (polyubiquitinated). Interacts with MYD88; the interaction
CC       is indicative for participation in an activated TLR-signaling complex.
CC       Interacts with HIV-1 matrix protein. Interacts with Shigella flexneri
CC       ipah9.8; the interaction promotes polyubiquitination of IKBKG.
CC       {ECO:0000269|PubMed:12220502, ECO:0000269|PubMed:16684768,
CC       ECO:0000269|PubMed:17632516, ECO:0000269|PubMed:20010814}.
CC   -!- INTERACTION:
CC       Q15025; Q9BXS5: AP1M1; NbExp=3; IntAct=EBI-357849, EBI-541426;
CC       Q15025; Q13895: BYSL; NbExp=8; IntAct=EBI-357849, EBI-358049;
CC       Q15025; Q9H7E9: C8orf33; NbExp=3; IntAct=EBI-357849, EBI-715389;
CC       Q15025; Q8NEF3: CCDC112; NbExp=3; IntAct=EBI-357849, EBI-745040;
CC       Q15025; P51959: CCNG1; NbExp=8; IntAct=EBI-357849, EBI-3905829;
CC       Q15025; Q9UJX2: CDC23; NbExp=3; IntAct=EBI-357849, EBI-396137;
CC       Q15025; Q16543: CDC37; NbExp=3; IntAct=EBI-357849, EBI-295634;
CC       Q15025; Q9H305: CDIP1; NbExp=4; IntAct=EBI-357849, EBI-2876678;
CC       Q15025; Q96M91: CFAP53; NbExp=3; IntAct=EBI-357849, EBI-742422;
CC       Q15025; A8MQ03: CYSRT1; NbExp=3; IntAct=EBI-357849, EBI-3867333;
CC       Q15025; Q15038: DAZAP2; NbExp=3; IntAct=EBI-357849, EBI-724310;
CC       Q15025; Q7L190: DPPA4; NbExp=3; IntAct=EBI-357849, EBI-710457;
CC       Q15025; Q08426: EHHADH; NbExp=4; IntAct=EBI-357849, EBI-2339219;
CC       Q15025; Q14241: ELOA; NbExp=3; IntAct=EBI-357849, EBI-742350;
CC       Q15025; Q3B820: FAM161A; NbExp=6; IntAct=EBI-357849, EBI-719941;
CC       Q15025; Q92567: FAM168A; NbExp=3; IntAct=EBI-357849, EBI-7957930;
CC       Q15025; Q9H0R8: GABARAPL1; NbExp=7; IntAct=EBI-357849, EBI-746969;
CC       Q15025; P60520: GABARAPL2; NbExp=6; IntAct=EBI-357849, EBI-720116;
CC       Q15025; Q14161: GIT2; NbExp=3; IntAct=EBI-357849, EBI-1046878;
CC       Q15025; Q00403: GTF2B; NbExp=7; IntAct=EBI-357849, EBI-389564;
CC       Q15025; Q8N4P3: HDDC3; NbExp=3; IntAct=EBI-357849, EBI-750003;
CC       Q15025; Q9Y6K9: IKBKG; NbExp=6; IntAct=EBI-357849, EBI-81279;
CC       Q15025; Q9BVG8: KIFC3; NbExp=3; IntAct=EBI-357849, EBI-2125614;
CC       Q15025; Q9BVG8-5: KIFC3; NbExp=3; IntAct=EBI-357849, EBI-14069005;
CC       Q15025; Q7Z4W3: KRTAP19-3; NbExp=3; IntAct=EBI-357849, EBI-12020132;
CC       Q15025; Q3LI72: KRTAP19-5; NbExp=3; IntAct=EBI-357849, EBI-1048945;
CC       Q15025; Q3SYF9: KRTAP19-7; NbExp=3; IntAct=EBI-357849, EBI-10241353;
CC       Q15025; Q3LI64: KRTAP6-1; NbExp=3; IntAct=EBI-357849, EBI-12111050;
CC       Q15025; Q3LI66: KRTAP6-2; NbExp=6; IntAct=EBI-357849, EBI-11962084;
CC       Q15025; Q8IUC2: KRTAP8-1; NbExp=3; IntAct=EBI-357849, EBI-10261141;
CC       Q15025; Q96PV6: LENG8; NbExp=3; IntAct=EBI-357849, EBI-739546;
CC       Q15025; Q99732: LITAF; NbExp=3; IntAct=EBI-357849, EBI-725647;
CC       Q15025; Q96M61: MAGEB18; NbExp=5; IntAct=EBI-357849, EBI-741835;
CC       Q15025; Q9H213: MAGEH1; NbExp=3; IntAct=EBI-357849, EBI-473834;
CC       Q15025; Q9H492: MAP1LC3A; NbExp=7; IntAct=EBI-357849, EBI-720768;
CC       Q15025; Q9GZQ8: MAP1LC3B; NbExp=4; IntAct=EBI-357849, EBI-373144;
CC       Q15025; Q9BXW4: MAP1LC3C; NbExp=3; IntAct=EBI-357849, EBI-2603996;
CC       Q15025; Q96EZ8: MCRS1; NbExp=3; IntAct=EBI-357849, EBI-348259;
CC       Q15025; Q7L9L4: MOB1B; NbExp=3; IntAct=EBI-357849, EBI-2558745;
CC       Q15025; Q70IA8: MOB3C; NbExp=3; IntAct=EBI-357849, EBI-9679267;
CC       Q15025; Q9UBU8: MORF4L1; NbExp=4; IntAct=EBI-357849, EBI-399246;
CC       Q15025; Q15014: MORF4L2; NbExp=4; IntAct=EBI-357849, EBI-399257;
CC       Q15025; O14777: NDC80; NbExp=9; IntAct=EBI-357849, EBI-715849;
CC       Q15025; P19838: NFKB1; NbExp=4; IntAct=EBI-357849, EBI-300010;
CC       Q15025; Q9BYG3: NIFK; NbExp=3; IntAct=EBI-357849, EBI-2561019;
CC       Q15025; Q9Y5B8: NME7; NbExp=8; IntAct=EBI-357849, EBI-744782;
CC       Q15025; Q96CV9: OPTN; NbExp=19; IntAct=EBI-357849, EBI-748974;
CC       Q15025; Q4G0R1: PIBF1; NbExp=3; IntAct=EBI-357849, EBI-14066006;
CC       Q15025; Q13526: PIN1; NbExp=7; IntAct=EBI-357849, EBI-714158;
CC       Q15025; Q96T60: PNKP; NbExp=6; IntAct=EBI-357849, EBI-1045072;
CC       Q15025; Q15311: RALBP1; NbExp=4; IntAct=EBI-357849, EBI-749285;
CC       Q15025; O76064: RNF8; NbExp=3; IntAct=EBI-357849, EBI-373337;
CC       Q15025; A0MZ66-4: SHTN1; NbExp=3; IntAct=EBI-357849, EBI-12097232;
CC       Q15025; Q8TAD8: SNIP1; NbExp=4; IntAct=EBI-357849, EBI-749336;
CC       Q15025; Q9UM82: SPATA2; NbExp=3; IntAct=EBI-357849, EBI-744066;
CC       Q15025; Q5T7P8-2: SYT6; NbExp=3; IntAct=EBI-357849, EBI-10246152;
CC       Q15025; Q86VP1: TAX1BP1; NbExp=8; IntAct=EBI-357849, EBI-529518;
CC       Q15025; Q15560: TCEA2; NbExp=8; IntAct=EBI-357849, EBI-710310;
CC       Q15025; Q8N8B7-2: TCEANC; NbExp=3; IntAct=EBI-357849, EBI-11955057;
CC       Q15025; Q96MN5: TCEANC2; NbExp=4; IntAct=EBI-357849, EBI-5462748;
CC       Q15025; P21580: TNFAIP3; NbExp=11; IntAct=EBI-357849, EBI-527670;
CC       Q15025; Q15025: TNIP1; NbExp=7; IntAct=EBI-357849, EBI-357849;
CC       Q15025; Q96KP6: TNIP3; NbExp=6; IntAct=EBI-357849, EBI-2509913;
CC       Q15025; Q99816: TSG101; NbExp=3; IntAct=EBI-357849, EBI-346882;
CC       Q15025; Q5SRH9-6: TTC39A; NbExp=3; IntAct=EBI-357849, EBI-12259184;
CC       Q15025; Q9UNY4-2: TTF2; NbExp=3; IntAct=EBI-357849, EBI-11980463;
CC       Q15025; P40222: TXLNA; NbExp=6; IntAct=EBI-357849, EBI-359793;
CC       Q15025; Q9H267: VPS33B; NbExp=9; IntAct=EBI-357849, EBI-749072;
CC       Q15025; Q15007: WTAP; NbExp=3; IntAct=EBI-357849, EBI-751647;
CC       Q15025; P24278: ZBTB25; NbExp=6; IntAct=EBI-357849, EBI-739899;
CC       Q15025; Q96NC0: ZMAT2; NbExp=3; IntAct=EBI-357849, EBI-2682299;
CC       Q15025; O43257: ZNHIT1; NbExp=3; IntAct=EBI-357849, EBI-347522;
CC       Q15025; Q8VSC3: ipaH9.8; Xeno; NbExp=4; IntAct=EBI-357849, EBI-6125799;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=Shuttles between the
CC       nucleus and cytoplasm in a CRM1-dependent manner.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=8;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=1; Synonyms=Alpha, FL;
CC         IsoId=Q15025-1; Sequence=Displayed;
CC       Name=2; Synonyms=Beta;
CC         IsoId=Q15025-2; Sequence=VSP_003913;
CC       Name=3;
CC         IsoId=Q15025-3; Sequence=VSP_045296;
CC       Name=4; Synonyms=Alpha2;
CC         IsoId=Q15025-4; Sequence=VSP_055208;
CC       Name=5; Synonyms=Alpha4;
CC         IsoId=Q15025-5; Sequence=VSP_055209, VSP_055214;
CC       Name=6; Synonyms=Beta2;
CC         IsoId=Q15025-6; Sequence=VSP_055208, VSP_003913;
CC       Name=7; Synonyms=Alpha3, Beta3;
CC         IsoId=Q15025-7; Sequence=VSP_055211, VSP_055212;
CC       Name=8; Synonyms=Beta4;
CC         IsoId=Q15025-8; Sequence=VSP_055210, VSP_055213;
CC   -!- TISSUE SPECIFICITY: Ubiquitous. Strongly expressed in peripheral blood
CC       lymphocytes, spleen and skeletal muscle, and is weakly expressed in the
CC       brain. In peripheral blood mononucleocytes, isoform 4 is mainly
CC       expressed and isoform 1 and isoform 7 are almost not expressed.
CC       Expression of isoform 1 and isoform 7 increases in leukemic cells.
CC       {ECO:0000269|PubMed:17016622}.
CC   -!- PTM: Phosphorylation at Tyr-552 by SRC-family kinases recruits
CC       phosphoinositide-3-kinase (PI3K) PIK3CD:p85 heterodimer which results
CC       in integrin activation and leukocyte adhesion to activated endothelium
CC       during inflammation. {ECO:0000269|PubMed:17632516}.
CC   -!- MISCELLANEOUS: [Isoform 5]: Less effective in the NF-kappa-B inhibitory
CC       effect. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB41438.1; Type=Frameshift; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AJ011895; CAA09855.1; -; mRNA.
DR   EMBL; AJ011896; CAA09856.1; -; mRNA.
DR   EMBL; AY012155; AAG42154.1; -; mRNA.
DR   EMBL; AB177543; BAF34946.1; -; mRNA.
DR   EMBL; AB177544; BAF34947.1; -; mRNA.
DR   EMBL; AB252970; BAF48787.1; -; mRNA.
DR   EMBL; AB252971; BAF48788.1; -; mRNA.
DR   EMBL; AB252972; BAF48789.1; -; mRNA.
DR   EMBL; AB252973; BAF48790.1; -; mRNA.
DR   EMBL; AB252974; BAF48791.1; -; mRNA.
DR   EMBL; AB252975; BAF48792.1; -; mRNA.
DR   EMBL; AB252976; BAF48793.1; -; mRNA.
DR   EMBL; AB252977; BAF48794.1; -; mRNA.
DR   EMBL; AB252978; BAF48795.1; -; mRNA.
DR   EMBL; AB252979; BAF48796.1; -; mRNA.
DR   EMBL; AB252980; BAF48797.1; -; mRNA.
DR   EMBL; AB252981; BAF48798.1; -; mRNA.
DR   EMBL; D30755; BAA06416.2; -; mRNA.
DR   EMBL; AK299975; BAH13185.1; -; mRNA.
DR   EMBL; BX640647; CAE45793.1; -; mRNA.
DR   EMBL; AC008641; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471062; EAW61688.1; -; Genomic_DNA.
DR   EMBL; CH471062; EAW61689.1; -; Genomic_DNA.
DR   EMBL; CH471062; EAW61690.1; -; Genomic_DNA.
DR   EMBL; CH471062; EAW61691.1; -; Genomic_DNA.
DR   EMBL; BC012133; AAH12133.1; -; mRNA.
DR   EMBL; BC014008; AAH14008.1; -; mRNA.
DR   EMBL; U39403; AAC99999.1; -; mRNA.
DR   EMBL; U83844; AAB41438.1; ALT_FRAME; mRNA.
DR   CCDS; CCDS34280.1; -. [Q15025-1]
DR   CCDS; CCDS58982.1; -. [Q15025-3]
DR   CCDS; CCDS58983.1; -. [Q15025-5]
DR   CCDS; CCDS58984.1; -. [Q15025-4]
DR   CCDS; CCDS58985.1; -. [Q15025-2]
DR   RefSeq; NP_001239314.1; NM_001252385.1.
DR   RefSeq; NP_001239315.1; NM_001252386.1. [Q15025-3]
DR   RefSeq; NP_001239319.1; NM_001252390.1. [Q15025-1]
DR   RefSeq; NP_001239320.1; NM_001252391.1. [Q15025-1]
DR   RefSeq; NP_001239321.1; NM_001252392.1. [Q15025-2]
DR   RefSeq; NP_001239322.1; NM_001252393.1. [Q15025-2]
DR   RefSeq; NP_001245383.1; NM_001258454.1. [Q15025-1]
DR   RefSeq; NP_001245384.1; NM_001258455.1. [Q15025-4]
DR   RefSeq; NP_001245385.1; NM_001258456.1. [Q15025-5]
DR   RefSeq; NP_006049.3; NM_006058.4. [Q15025-1]
DR   RefSeq; XP_006714814.1; XM_006714751.1.
DR   RefSeq; XP_006714815.1; XM_006714752.2. [Q15025-6]
DR   SMR; Q15025; -.
DR   BioGRID; 115602; 186.
DR   CORUM; Q15025; -.
DR   DIP; DIP-27577N; -.
DR   IntAct; Q15025; 163.
DR   MINT; Q15025; -.
DR   STRING; 9606.ENSP00000317891; -.
DR   iPTMnet; Q15025; -.
DR   PhosphoSitePlus; Q15025; -.
DR   BioMuta; TNIP1; -.
DR   DMDM; 20138952; -.
DR   EPD; Q15025; -.
DR   jPOST; Q15025; -.
DR   MassIVE; Q15025; -.
DR   MaxQB; Q15025; -.
DR   PaxDb; Q15025; -.
DR   PeptideAtlas; Q15025; -.
DR   PRIDE; Q15025; -.
DR   ProteomicsDB; 17465; -.
DR   ProteomicsDB; 18155; -.
DR   ProteomicsDB; 60376; -. [Q15025-1]
DR   ProteomicsDB; 60377; -. [Q15025-2]
DR   ProteomicsDB; 66620; -.
DR   Antibodypedia; 28121; 295 antibodies.
DR   DNASU; 10318; -.
DR   Ensembl; ENST00000315050; ENSP00000317891; ENSG00000145901. [Q15025-1]
DR   Ensembl; ENST00000518977; ENSP00000430971; ENSG00000145901. [Q15025-2]
DR   Ensembl; ENST00000520931; ENSP00000429891; ENSG00000145901. [Q15025-3]
DR   Ensembl; ENST00000521591; ENSP00000430760; ENSG00000145901. [Q15025-1]
DR   Ensembl; ENST00000522226; ENSP00000428187; ENSG00000145901. [Q15025-1]
DR   Ensembl; ENST00000523200; ENSP00000431105; ENSG00000145901. [Q15025-4]
DR   Ensembl; ENST00000523338; ENSP00000428243; ENSG00000145901. [Q15025-2]
DR   Ensembl; ENST00000524280; ENSP00000429912; ENSG00000145901. [Q15025-5]
DR   Ensembl; ENST00000610535; ENSP00000483944; ENSG00000145901. [Q15025-4]
DR   Ensembl; ENST00000610874; ENSP00000484665; ENSG00000145901. [Q15025-5]
DR   GeneID; 10318; -.
DR   KEGG; hsa:10318; -.
DR   UCSC; uc003ltg.5; human. [Q15025-1]
DR   CTD; 10318; -.
DR   DisGeNET; 10318; -.
DR   GeneCards; TNIP1; -.
DR   HGNC; HGNC:16903; TNIP1.
DR   HPA; ENSG00000145901; Low tissue specificity.
DR   MalaCards; TNIP1; -.
DR   MIM; 607714; gene.
DR   neXtProt; NX_Q15025; -.
DR   OpenTargets; ENSG00000145901; -.
DR   Orphanet; 536; Systemic lupus erythematosus.
DR   PharmGKB; PA128394573; -.
DR   VEuPathDB; HostDB:ENSG00000145901.14; -.
DR   eggNOG; ENOG502QPYT; Eukaryota.
DR   GeneTree; ENSGT00510000046908; -.
DR   HOGENOM; CLU_033970_0_0_1; -.
DR   InParanoid; Q15025; -.
DR   OMA; WRPPCAM; -.
DR   OrthoDB; 701614at2759; -.
DR   PhylomeDB; Q15025; -.
DR   TreeFam; TF351138; -.
DR   PathwayCommons; Q15025; -.
DR   Reactome; R-HSA-5689896; Ovarian tumor domain proteases.
DR   BioGRID-ORCS; 10318; 15 hits in 998 CRISPR screens.
DR   ChiTaRS; TNIP1; human.
DR   GeneWiki; TNIP1; -.
DR   GenomeRNAi; 10318; -.
DR   Pharos; Q15025; Tbio.
DR   PRO; PR:Q15025; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   RNAct; Q15025; protein.
DR   Bgee; ENSG00000145901; Expressed in amniotic fluid and 246 other tissues.
DR   ExpressionAtlas; Q15025; baseline and differential.
DR   Genevisible; Q15025; HS.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0051019; F:mitogen-activated protein kinase binding; IDA:UniProtKB.
DR   GO; GO:0031593; F:polyubiquitin modification-dependent protein binding; IBA:GO_Central.
DR   GO; GO:0006952; P:defense response; TAS:ProtInc.
DR   GO; GO:0009101; P:glycoprotein biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW.
DR   GO; GO:0007159; P:leukocyte cell-cell adhesion; IMP:UniProtKB.
DR   GO; GO:0085032; P:modulation by symbiont of host I-kappaB kinase/NF-kappaB cascade; IDA:UniProtKB.
DR   GO; GO:0002755; P:MyD88-dependent toll-like receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0070373; P:negative regulation of ERK1 and ERK2 cascade; IDA:UniProtKB.
DR   GO; GO:0043124; P:negative regulation of I-kappaB kinase/NF-kappaB signaling; IDA:UniProtKB.
DR   GO; GO:0045071; P:negative regulation of viral genome replication; TAS:UniProtKB.
DR   GO; GO:0050729; P:positive regulation of inflammatory response; ISS:UniProtKB.
DR   GO; GO:1903003; P:positive regulation of protein deubiquitination; IDA:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; ISS:UniProtKB.
DR   GO; GO:0016579; P:protein deubiquitination; TAS:Reactome.
DR   GO; GO:0006412; P:translation; TAS:ProtInc.
DR   InterPro; IPR033372; TNIP1.
DR   PANTHER; PTHR31882:SF3; PTHR31882:SF3; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Coiled coil; Cytoplasm; Inflammatory response;
KW   Methylation; Nucleus; Phosphoprotein; Reference proteome.
FT   CHAIN           1..636
FT                   /note="TNFAIP3-interacting protein 1"
FT                   /id="PRO_0000096691"
FT   REGION          94..412
FT                   /note="Interaction with Nef"
FT   REGION          351..367
FT                   /note="Interaction with Shigella flexneri ipah9.8"
FT   REGION          431..588
FT                   /note="Required for inhibitory activity of TNF-induced NF-
FT                   kappa-B activation"
FT                   /evidence="ECO:0000250"
FT   REGION          452..510
FT                   /note="Ubiquitin-binding domain (UBD)"
FT   COILED          20..73
FT                   /evidence="ECO:0000255"
FT   COILED          196..258
FT                   /evidence="ECO:0000255"
FT   COILED          294..535
FT                   /evidence="ECO:0000255"
FT   MOTIF           524..530
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        539..636
FT                   /note="Pro-rich"
FT   MOD_RES         77
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         284
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         403
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:16964243,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         438
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         442
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         552
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:17632516"
FT   MOD_RES         571
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9WUU8"
FT   MOD_RES         599
FT                   /note="Asymmetric dimethylarginine; alternate"
FT                   /evidence="ECO:0007744|PubMed:24129315"
FT   MOD_RES         599
FT                   /note="Omega-N-methylarginine; alternate"
FT                   /evidence="ECO:0007744|PubMed:24129315"
FT   MOD_RES         627
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   VAR_SEQ         1..53
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:17016622, ECO:0000303|PubMed:17974005"
FT                   /id="VSP_045296"
FT   VAR_SEQ         530..593
FT                   /note="Missing (in isoform 4 and isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:17016622"
FT                   /id="VSP_055208"
FT   VAR_SEQ         530..556
FT                   /note="ASGERYHVEPHPEHLCGAYPYAYPPMP -> SLQKMTVRGLSETRLCHLAPP
FT                   SSCRAS (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:17016622"
FT                   /id="VSP_055209"
FT   VAR_SEQ         530..552
FT                   /note="ASGERYHVEPHPEHLCGAYPYAY -> SQLISDCQETRSHLHGVARASAG
FT                   (in isoform 8)"
FT                   /evidence="ECO:0000303|PubMed:17016622"
FT                   /id="VSP_055210"
FT   VAR_SEQ         530..545
FT                   /note="ASGERYHVEPHPEHLC -> GTHRGCPRRLPERKVK (in isoform 7)"
FT                   /evidence="ECO:0000303|PubMed:17016622"
FT                   /id="VSP_055211"
FT   VAR_SEQ         546..636
FT                   /note="Missing (in isoform 7)"
FT                   /evidence="ECO:0000303|PubMed:17016622"
FT                   /id="VSP_055212"
FT   VAR_SEQ         553..636
FT                   /note="Missing (in isoform 8)"
FT                   /evidence="ECO:0000303|PubMed:17016622"
FT                   /id="VSP_055213"
FT   VAR_SEQ         557..636
FT                   /note="Missing (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:17016622"
FT                   /id="VSP_055214"
FT   VAR_SEQ         627..636
FT                   /note="SPKNDREGPQ -> PADLRLPRN (in isoform 2 and isoform
FT                   6)"
FT                   /evidence="ECO:0000303|PubMed:17016622,
FT                   ECO:0000303|PubMed:8681136, ECO:0000303|PubMed:9923610"
FT                   /id="VSP_003913"
FT   VARIANT         103
FT                   /note="P -> S (in dbSNP:rs2303018)"
FT                   /id="VAR_051453"
FT   VARIANT         146
FT                   /note="A -> V (in dbSNP:rs2233289)"
FT                   /id="VAR_051454"
FT   VARIANT         151
FT                   /note="P -> A (in dbSNP:rs2233290)"
FT                   /id="VAR_051455"
FT   VARIANT         233
FT                   /note="R -> Q (in dbSNP:rs2233292)"
FT                   /id="VAR_051456"
FT   VARIANT         260
FT                   /note="A -> V (in dbSNP:rs2233295)"
FT                   /id="VAR_051457"
FT   VARIANT         263
FT                   /note="R -> W (in patients with gastrointestinal diffuse
FT                   large cell lymphoma; dbSNP:rs117663772)"
FT                   /evidence="ECO:0000269|PubMed:21266526"
FT                   /id="VAR_067965"
FT   VARIANT         286
FT                   /note="T -> M (in patients with gastrointestinal diffuse
FT                   large cell lymphoma; somatic mutation; dbSNP:rs185683917)"
FT                   /evidence="ECO:0000269|PubMed:21266526"
FT                   /id="VAR_067966"
FT   VARIANT         374
FT                   /note="I -> T (in patients with gastrointestinal diffuse
FT                   large cell lymphoma; dbSNP:rs748495842)"
FT                   /evidence="ECO:0000269|PubMed:21266526"
FT                   /id="VAR_067967"
FT   VARIANT         476
FT                   /note="E -> K (in patients with gastrointestinal diffuse
FT                   large cell lymphoma; somatic mutation; loss of inhibitory
FT                   activity on CARD11- and TNF-induced NF-kappa-B activation)"
FT                   /evidence="ECO:0000269|PubMed:21266526"
FT                   /id="VAR_067968"
FT   MUTAGEN         472
FT                   /note="D->N: Abolishes binding to polyubiquitin ('K-63'-
FT                   linked and linear)."
FT                   /evidence="ECO:0000269|PubMed:21606507"
FT   MUTAGEN         552
FT                   /note="Y->F: Abolishes interaction with PI3K p85 regulatory
FT                   subunit and abolishes interaction between SELPLG and PI3K
FT                   p85 regulatory subunit."
FT                   /evidence="ECO:0000269|PubMed:17632516"
FT   CONFLICT        148
FT                   /note="G -> D (in Ref. 10; AAH12133)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        178
FT                   /note="G -> S (in Ref. 6; BAH13185)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        299
FT                   /note="A -> P (in Ref. 2; AAG42154 and 3; BAF34946)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   636 AA;  71864 MW;  D81B96BEAD50D871 CRC64;
     MEGRGPYRIY DPGGSVPSGE ASAAFERLVK ENSRLKEKMQ GIKMLGELLE ESQMEATRLR
     QKAEELVKDN ELLPPPSPSL GSFDPLAELT GKDSNVTASP TAPACPSDKP APVQKPPSSG
     TSSEFEVVTP EEQNSPESSS HANAMALGPL PREDGNLMLH LQRLETTLSV CAEEPDHGQL
     FTHLGRMALE FNRLASKVHK NEQRTSILQT LCEQLRKENE ALKAKLDKGL EQRDQAAERL
     REENLELKKL LMSNGNKEGA SGRPGSPKME GTGKKAVAGQ QQASVTAGKV PEVVALGAAE
     KKVKMLEQQR SELLEVNKQW DQHFRSMKQQ YEQKITELRQ KLADLQKQVT DLEAEREQKQ
     RDFDRKLLLA KSKIEMEETD KEQLTAEAKE LRQKVKYLQD QLSPLTRQRE YQEKEIQRLN
     KALEEALSIQ TPPSSPPTAF GSPEGAGALL RKQELVTQNE LLKQQVKIFE EDFQRERSDR
     ERMNEEKEEL KKQVEKLQAQ VTLSNAQLKA FKDEEKAREA LRQQKRKAKA SGERYHVEPH
     PEHLCGAYPY AYPPMPAMVP HHGFEDWSQI RYPPPPMAME HPPPLPNSRL FHLPEYTWRL
     PCGGVRNPNQ SSQVMDPPTA RPTEPESPKN DREGPQ
//
